Regeneron and Sanofi restructure immuno-oncology collaboration
Regeneron and Sanofi have restructured their global immuno-oncology discovery and development agreement for new immuno-oncology cancer treatments, with Sanofi set to pay $462 million to end the collaboration early.
Read More




